Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pancreatic neoplasms include different pathological entities with variable biological behavior and different treatment modalities. Surgery and adjuvant therapy are the cornerstones of the therapeutic approach; however, even after radical resection, the majority of patients experience disease recurrence and the prognosis of pancreatic cancer remains dismal. A multimodal therapeutic approach, based on a combination of neoadjuvant therapy, chemotherapy, radiotherapy, immunotherapy and surgery, appears fundamental to improving the outcomes. This Special Issue of the Journal of Clinical Medicine, entitled “Recent Advances in Pancreatic Neoplasms”, focuses on possible new strategies to treat pancreatic neoplasms.

Medicine --- Oncology --- PIWI proteins --- PIWIL3 --- PIWIL4 --- pancreatic cancer --- EMT --- chemoresistance --- motility --- HNF4A --- survival --- pancreatic neuroendocrine neoplasm --- primary pancreatic carcinoid --- serotonin-secreting pancreatic tumour --- serotonin-producing pancreatic tumour --- neoadjuvant chemotherapy --- response --- carbohydrate antigen 19-9 --- fluorodeoxyglucose --- pancreatectomy --- positron emission tomography --- prognosis --- standardized uptake value --- Pancreatic ductal adenocarcinoma --- microRNAs --- pancreatic fistula --- pancreatic neoplasm --- renal cell carcinoma --- pancreatic neoplasms --- PET-CT scan --- pancreatic ductal adenocarcinoma --- pancreatic cancer prognosis --- completion total pancreatectomy --- pooled analysis --- recurrent pancreatic cancer --- repeated pancreatectomy --- pancreas --- neuropathy --- taxanes --- biomarker --- C-reactive protein to albumin ratio --- inflammation --- intraductal papillary mucinous neoplasm --- modified Glasgow prognostic score --- neutrophyl lymphocite ratio --- platelet-to-lymphocyte ratio --- robotic pancreatic surgery --- pancreato-gastrostomy --- low muscle mass --- sarcopenia --- pancreatic adenocarcinoma --- pancreatic surgery --- body composition --- PIWI proteins --- PIWIL3 --- PIWIL4 --- pancreatic cancer --- EMT --- chemoresistance --- motility --- HNF4A --- survival --- pancreatic neuroendocrine neoplasm --- primary pancreatic carcinoid --- serotonin-secreting pancreatic tumour --- serotonin-producing pancreatic tumour --- neoadjuvant chemotherapy --- response --- carbohydrate antigen 19-9 --- fluorodeoxyglucose --- pancreatectomy --- positron emission tomography --- prognosis --- standardized uptake value --- Pancreatic ductal adenocarcinoma --- microRNAs --- pancreatic fistula --- pancreatic neoplasm --- renal cell carcinoma --- pancreatic neoplasms --- PET-CT scan --- pancreatic ductal adenocarcinoma --- pancreatic cancer prognosis --- completion total pancreatectomy --- pooled analysis --- recurrent pancreatic cancer --- repeated pancreatectomy --- pancreas --- neuropathy --- taxanes --- biomarker --- C-reactive protein to albumin ratio --- inflammation --- intraductal papillary mucinous neoplasm --- modified Glasgow prognostic score --- neutrophyl lymphocite ratio --- platelet-to-lymphocyte ratio --- robotic pancreatic surgery --- pancreato-gastrostomy --- low muscle mass --- sarcopenia --- pancreatic adenocarcinoma --- pancreatic surgery --- body composition

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pancreatic neoplasms include different pathological entities with variable biological behavior and different treatment modalities. Surgery and adjuvant therapy are the cornerstones of the therapeutic approach; however, even after radical resection, the majority of patients experience disease recurrence and the prognosis of pancreatic cancer remains dismal. A multimodal therapeutic approach, based on a combination of neoadjuvant therapy, chemotherapy, radiotherapy, immunotherapy and surgery, appears fundamental to improving the outcomes. This Special Issue of the Journal of Clinical Medicine, entitled “Recent Advances in Pancreatic Neoplasms”, focuses on possible new strategies to treat pancreatic neoplasms.

PIWI proteins --- PIWIL3 --- PIWIL4 --- pancreatic cancer --- EMT --- chemoresistance --- motility --- HNF4A --- survival --- pancreatic neuroendocrine neoplasm --- primary pancreatic carcinoid --- serotonin-secreting pancreatic tumour --- serotonin-producing pancreatic tumour --- neoadjuvant chemotherapy --- response --- carbohydrate antigen 19-9 --- fluorodeoxyglucose --- pancreatectomy --- positron emission tomography --- prognosis --- standardized uptake value --- Pancreatic ductal adenocarcinoma --- microRNAs --- pancreatic fistula --- pancreatic neoplasm --- renal cell carcinoma --- pancreatic neoplasms --- PET-CT scan --- pancreatic ductal adenocarcinoma --- pancreatic cancer prognosis --- completion total pancreatectomy --- pooled analysis --- recurrent pancreatic cancer --- repeated pancreatectomy --- pancreas --- neuropathy --- taxanes --- biomarker --- C-reactive protein to albumin ratio --- inflammation --- intraductal papillary mucinous neoplasm --- modified Glasgow prognostic score --- neutrophyl lymphocite ratio --- platelet-to-lymphocyte ratio --- robotic pancreatic surgery --- pancreato-gastrostomy --- low muscle mass --- sarcopenia --- pancreatic adenocarcinoma --- pancreatic surgery --- body composition --- n/a